Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

Karyopharm (Nasdaq:KPTI) will host an investor conference call on June 2, 2026 at 2:00 p.m. ET to discuss the Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis, following an oral presentation at the 2026 ASCO Annual Meeting.

Rhea-AI Summary

Karyopharm (Nasdaq:KPTI) will host an investor conference call on June 2, 2026 at 2:00 p.m. ET to discuss the Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis, following an oral presentation at the 2026 ASCO Annual Meeting.

The event features Karyopharm's senior management and Dr. John Mascarenhas, SENTRY principal investigator. Investors can join via phone or a live audio webcast with slides under “Events & Presentations” in the investor section of Karyopharm’s website, with an archived replay available about two hours after the call.

Argus Jun 1 session

+7.91% close to close Open Argus

Details

News Market Reaction – KPTI

In the Jun 1 session, KPTI gained 7.91%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +7.9% in the session following this news. A strong positive reaction aligns with gro...

Analysis

The stock moved +7.9% in the session following this news. A strong positive reaction aligns with growing focus on the Phase 3 SENTRY myelofibrosis data and its late-breaking ASCO profile. Prior ASCO-related news produced a 2.57% gain, and recent earnings and conference updates also drew supportive moves. However, investors must weigh that an effective S-3 registers resale of 8,843,036 shares from a recent financing, which could influence supply dynamics if enthusiasm fades.

Key Figures

Q1 2026 revenue: $35.1 million U.S. XPOVIO revenue: $29.2 million 2026 revenue guidance: $130–$150 million +5 more

Q1 2026 revenue

$35.1 million

First quarter 2026 total revenue

U.S. XPOVIO revenue

$29.2 million

Q1 2026 net product revenue

2026 revenue guidance

$130–$150 million

Full-year 2026 guidance reaffirmed

Selinexor dose

60 mg selinexor

Phase 3 SENTRY trial in myelofibrosis

Registered shares

8,843,036 shares

Resale registration on Form S-3

Private placement proceeds

$30 million

March 2026 private placement gross proceeds

Equity plan increase

3,000,000 shares

Added to 2022 Equity Incentive Plan

ESPP increase

1,400,000 shares

Added to Employee Stock Purchase Plan

Historical Context

5 past events · Latest: May 28

5 events

1. May 28

   Investor conference

   24h Move

   +1.4%

   Jefferies Global Healthcare Conference fireside chat announcement and webcast access.

2. May 14

   Earnings and trials

   24h Move

   +0.6%

   Q1 2026 results, reaffirmed guidance, and Phase 3 endometrial trial enrollment completion.

3. May 12

   Investor conferences

   24h Move

   +1.2%

   Participation in two May 2026 healthcare investor conferences with live webcasts.

4. May 07

   Earnings date set

   24h Move

   -1.9%

   Scheduling of Q1 2026 earnings release and investor call details.

5. Apr 21

   ASCO selection

   24h Move

   +2.6%

   Phase 3 SENTRY myelofibrosis trial chosen for late-breaking ASCO 2026 oral presentation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 3, myelofibrosis

2 terms

phase 3 medical

"Principal Investigator of the Phase 3 SENTRY Trial –– Conference Call Scheduled"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

myelofibrosis medical

"results from the Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis"

A bone marrow disorder in which healthy, spongy marrow is gradually replaced by scar tissue, like a garden soil turned to concrete so seeds can’t grow. That replacement reduces production of red and white blood cells and platelets, causing anemia, fatigue, infections and an enlarged spleen. Investors care because the condition creates demand for therapies, clinical trials and regulatory decisions that can materially affect drug sales and company valuations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial –

– Conference Call Scheduled for Tuesday, June 2, 2026 at 2:00 p.m. ET –

NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will host a conference call on June 2, 2026 at 2:00 p.m. ET featuring the Company's senior management team and Dr. John Mascarenhas, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders, and principal investigator of the Phase 3 SENTRY trial. The call will discuss the results from the Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis and will follow Dr. Mascarenhas' oral presentation of the results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic and solid tumor cancers, including in myelofibrosis and TP53 wild-type endometrial cancer. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm. 

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-host-investor-conference-call-featuring-expert-perspectives-on-the-phase-3-sentry-trial-in-myelofibrosis-following-2026-asco-presentation-302786581.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When is Karyopharm's (KPTI) investor call on the Phase 3 SENTRY trial in myelofibrosis?

The Karyopharm investor call is scheduled for June 2, 2026 at 2:00 p.m. ET. According to Karyopharm, the call will follow the SENTRY Phase 3 selinexor plus ruxolitinib presentation at the 2026 ASCO Annual Meeting.

How can investors access Karyopharm's June 2, 2026 SENTRY trial conference call (KPTI)?

Investors can join by dialing (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes early. According to Karyopharm, a live audio webcast with slides will also be available under “Events & Presentations” on the company’s investor website.

Who will participate in Karyopharm's Phase 3 SENTRY trial investor call for KPTI shareholders?

The call will feature Karyopharm’s senior management and Dr. John Mascarenhas, the SENTRY trial principal investigator. According to Karyopharm, Dr. Mascarenhas is a Professor of Medicine and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at Mount Sinai.

What will be discussed on Karyopharm's June 2, 2026 SENTRY trial call about selinexor plus ruxolitinib?

The call will review results from the Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis. According to Karyopharm, the discussion will occur after Dr. Mascarenhas’ oral SENTRY results presentation at the 2026 ASCO Annual Meeting.

Will a replay of Karyopharm's June 2, 2026 investor conference call on SENTRY (KPTI) be available?

Yes, an archived webcast of the investor call will be available on Karyopharm’s website. According to Karyopharm, the replay should be accessible under the “Events & Presentations” section approximately two hours after the event concludes.

Where can KPTI investors find the webcast and slides for Karyopharm's SENTRY Phase 3 call?

KPTI investors can access the live audio webcast and accompanying slides in the Investor section of Karyopharm’s website. According to Karyopharm, these materials will be listed under “Events & Presentations” for the June 2, 2026 conference call.